Unicycive Therapeutics (NASDAQ:UNCY) Rating Lowered to “Strong Sell” at Zacks Research

Posted by Brenda Bartman on Jul 23rd, 2026

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Tuesday,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. B. Riley Financial reissued a “buy” rating and issued a $22.00 price target on shares of Unicycive Therapeutics in a report on Tuesday, June 30th. HC Wainwright reduced their price objective on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Guggenheim reaffirmed a “buy” rating and set a $37.00 price objective (down from $40.00) on shares of Unicycive Therapeutics in a report on Wednesday, May 13th. Wall Street Zen lowered shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, Weiss Ratings raised shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 9th. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $21.75.

Read Our Latest Analysis on Unicycive Therapeutics

Unicycive Therapeutics Trading Down 2.1%

Shares of NASDAQ:UNCY opened at $5.57 on Tuesday. Unicycive Therapeutics has a 1-year low of $3.71 and a 1-year high of $8.74. The firm has a market capitalization of $152.56 million, a PE ratio of -2.52 and a beta of 1.79. The business’s 50 day moving average is $6.76 and its 200-day moving average is $6.77.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.08). On average, sell-side analysts predict that Unicycive Therapeutics will post -1.49 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in UNCY. Cantor Fitzgerald L. P. acquired a new stake in shares of Unicycive Therapeutics during the 4th quarter worth about $1,154,000. OMERS ADMINISTRATION Corp bought a new position in Unicycive Therapeutics during the 4th quarter valued at about $451,000. State Street Corp boosted its position in Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after buying an additional 10,400 shares in the last quarter. Geode Capital Management LLC boosted its position in Unicycive Therapeutics by 36.2% in the fourth quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock valued at $989,000 after buying an additional 45,563 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Unicycive Therapeutics in the third quarter valued at about $182,000. 40.42% of the stock is owned by institutional investors.

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.